Shalaev S V, Safiullina Z M, Zhuravleva T D, Nikitina V I, Baranova T A
Kardiologiia. 1992 Jun;32(6):19-21.
The impact of a 4-week course of lovastatin (mevacor) therapy on platelet function was examined in 26 patients with coronary heart disease concurrent with hypercholesterolemia (the baseline plasma cholesterol level was 250 mg% or more). The agent was given in a daily dose of 20-40 mg. The agent in this dose was found to have no action on the thromboxane-prostacyclin balance in plasma, on the degree of ADP-induced aggregation and lipid peroxidation in platelets, phospholipid composition and levels of ester-bound cholesterol in platelet membranes. Free cholesterol tended to increase at the end of the 4th week of treatment. Despite the effective reduction of plasma levels of total and LDL cholesterols whose action on platelets is well known, there was no estimated decrease in the activity of platelets during lovastatin therapy.
对26例冠心病合并高胆固醇血症（基线血浆胆固醇水平为250mg%或更高）患者，研究了为期4周的洛伐他汀（美降之）治疗对血小板功能的影响。该药每日剂量为20 - 40mg。发现该剂量的药物对血浆中血栓素 - 前列环素平衡、血小板中ADP诱导的聚集程度和脂质过氧化、血小板膜中的磷脂组成以及酯结合胆固醇水平均无作用。治疗第4周结束时，游离胆固醇有升高趋势。尽管洛伐他汀有效降低了血浆总胆固醇和低密度脂蛋白胆固醇水平，其对血小板的作用也为人熟知，但在洛伐他汀治疗期间，未估计到血小板活性下降。
